HIGHLIGHTS
- who: Francesco Muntoni et al. from the Health, College London, and Great Ormond Street Hospital Trust, London, United Kingdom, The have published the research: Novel approaches to analysis of the North Star Ambulatory Assessment (NSAA) in Duchenne muscular dystrophy (DMD): Observations from a phase 2 trial, in the Journal: PLOS ONE of November/16,/2021
- what: Because many DMD clinical trials used 6MWT as the primary endpoint, the authors explore the relationship between NSAA total score and 6MWT in domagrozumab-treated patients. The aim of the current analyses was to explore the utility of the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.